The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III GCIG trial.
S. Mahner
Consultant or Advisory Role - Essex Pharma
Honoraria - Essex Pharma; Merck Sharp & Dohme; PharmaMar
W. Meier
No relevant relationships to disclose
A. Du Bois
Consultant or Advisory Role - AstraZeneca; Johnson & Johnson; PharmaMar; Roche
Honoraria - Schering-Plough
Research Funding - Schering-Plough
C. Brown
No relevant relationships to disclose
D. Lorusso
No relevant relationships to disclose
A. Ferrero
No relevant relationships to disclose
J. Cretin
No relevant relationships to disclose
H. Havsteen
No relevant relationships to disclose
P. Bessette
No relevant relationships to disclose
L. Angleitner-Boubenizek
No relevant relationships to disclose
I. B. Vergote
No relevant relationships to disclose
P. A. Vasey
No relevant relationships to disclose
V. Gebski
No relevant relationships to disclose
B. Slama
No relevant relationships to disclose
J. Herrstedt
No relevant relationships to disclose
L. Kaizer
No relevant relationships to disclose
A. Georgoulopoulos
No relevant relationships to disclose
N. Reed
Consultant or Advisory Role - Johnson & Johnson; Novartis; Otsuka; Schering-Plough
U. Wagner
Honoraria - Schering-Plough